🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Business news, market intelligence, and global industry analysis.
The Latest

Themis Medicare, NFL Biosciences partner on smoking cessation candidate NFL-101

byPallavi Madhiraju
October 10, 2022
Total
0
Shares
0
0
0

Indian pharmaceutical company Themis Medicare has joined hands with French biotech company NFL Biosciences to develop NFL-101, a drug candidate for smoking cessation for the Indian market.

Themis Medicare submitted an investigational new drug application for NFL-101 phase 2/3 clinical trial to the Central Drugs Standard Control Organization, the National Regulatory Authority of India.

After the approval, the clinical trial will be done in India targeting 334 smokers. The expenses of the process from submission to completion of the study will be borne by Themis Medicare.

The NFL-101 active pharmaceutical ingredient will be bought by Themis Medicare from NFL Biosciences with the latter also to get double-digit royalties on sales.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Leucadia launches Sodium Tetradecyl Sulfate injection for varicose veins
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Mallinckrodt to sell Canadian CDMO BioVectra to H.I.G. Capital for $250m

Mallinckrodt sale of BioVectra to H.I.G. Capital : Irish biopharma company Mallinckrodt has agreed to divest its wholly-owned subsidiary BioVectra, a Canadian CDMO (contract development and manufacturing organization) to an affiliate of H.I.G. Capital for nearly US$250 million, as per the latest pharma acquisition news. The transaction amount to be paid by H.I.G. Capital, which is […]

The post Mallinckrodt to sell Canadian CDMO BioVectra to H.I.G. Capital for $250m appeared first on PharmaNewsDaily.com.

bySrinath